A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)

Gottsegen Gyorgy Hungarian, Budapest

Semmelweis Karlocai, Budapest

St. Vincent's Hospital, Darlinghurst

The Alfred Hospital, Melbourne

The Prince Charles Hospital, Chermside

University of Debrecen, Debrecen

University of Szeged, Szeged

Royal Hobart Hospital, Hobart

University of Pittsburgh Medical Center, Pittsburgh

University of Maryland Medical Center, Baltimore

Inova Fairfax Hospital, Falls Church

Duke University Medical Center, Durham

Kentuckiana Pulmonary Associates, Louisville

The Ohio State University Medical Center, Columbus

University of Cincinnati, Cincinnati

Aurora St. Luke's Medical Center, Milwaukee

University of Texas Southwestern Medical Center, Dallas

Baylor College of Medicine, Houston

University of Colorado Denver, Aurora

UCLA Medical Center, Torrance

UCSD Medical Center, La Jolla

Tufts Medical Center, Boston

Brigham and Women's Hospital, Boston

Boston University School of Medicine, Boston

Washington University School of Medicine, St Louis